Climb Bio, Inc. (CLYM) · Nov 5, 2026 · Earnings
Beat — GAAP EPS $(0.18) vs ~$ (0.20) consensus
Climb Bio’s earnings narrowly beat consensus while CLYM116 and budoprutug stay on track for key 2027 clinical readouts.
Climb Bio is a clinical-stage biotech moving two antibody programs through early clinical development: CLYM116 toward Phase 2/3 in IgA nephropathy and budoprutug across kidney and autoimmune diseases. The prior setup already called for CLYM116 Phase 2 dosing in the third quarter and multiple budoprutug readouts in the fourth quarter, so this filing mostly confirms execution against that plan rather than introducing a surprise.
| Q3 2026 | Q3 2025 | Consensus | |
|---|---|---|---|
| Net loss per share, basic and diluted (Income Statement) | $(0.18) | $(0.19) | $(0.20) |
| R&D expenses (Income Statement) | $11.0M | $9.1M | |
| G&A expenses (Income Statement) | $5.8M | $5.8M | |
| Net loss (Income Statement) | $(14.6M) | $(12.9M) |
The financial beat is real but small. GAAP loss per share was $0.18, modestly better than the published consensus near $0.20 loss; the company has no product revenue, so the quarter is judged mainly on spending and pipeline progress rather than commercial growth. R&D spending rose as programs advanced, while G&A was flat. The loss therefore clears the narrow earnings bar but does not materially change the underlying biotech story.
The main business update is execution, not a new clinical breakthrough. Climb Bio has started dosing NAVIGATE-2, its Phase 2 IgA nephropathy study of CLYM116, with initial data still targeted for the first half of 2027. 〔0〕 That keeps the program on the previously outlined timetable; the more important test—whether healthy-volunteer pharmacology translates into patient biomarker and kidney outcomes—remains ahead.
Budoprutug is generating encouraging early signals, but the evidence is still small and biomarker-heavy. In pMN, the 200 mg cohort showed B-cell depletion, lower PLA2R antibodies, and immunologic remission at 12 weeks, while higher-dose cohorts are being explored because proteinuric patients clear the drug faster. In SLE, the 100 mg cohort produced an 84% mean B-cell reduction at Week 12 and activity-score improvements in seven of 12 patients at 30 mg and 100 mg. 〔1〕 Those findings strengthen the platform narrative, but they do not yet establish clinical efficacy in controlled trials.
The balance sheet removes near-term financing pressure. Cash, cash equivalents, and marketable securities were $227.6million as of September 30, 2026. Management says that funds operations into the second half of 2028, broadly consistent with the runway communicated after the company’s earlier financing. That gives Climb Bio room to reach the 2027 readouts without an immediate capital event, although the runway remains management’s estimate and development spending is rising.
Bottom line: This is a modestly positive execution quarter, not a story-resetting event. Climb Bio beat a low financial bar and kept both programs moving toward important 2027 data, but most of the clinical direction was already known and the decisive patient-efficacy proof is still ahead.
ITP data at ASH, December 2026
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!